Findings

What do systematic reviews say?

1,615 questions · 1,673 findings · 190 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 278 · 16.6%GRADE not reported 85 · 5.1%Very low 328 · 19.6%Low 460 · 27.5%Moderate 402 · 24%High 120 · 7.2%

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission at 9 months among those whose HIV diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
HR 1.23 [0.83, 1.81]
1 study · 2013 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infant Mortality at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in infant Mortality at 9 months among those whose HIV diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
HR 0.91 [0.61, 1.36]
1 study · 2013 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
HR 1.04 [0.71, 1.51]
1 study · 1122 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission or Death at 9 months among those whose HIV diagnostic testing was negative within 48 hours of birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission or Death at 9 months among those whose HIV… compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
HR 1.09 [0.82, 1.44]
1 study · 2013 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infant Mortality at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in infant Mortality at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
HR 0.91 [0.61, 1.36]
1 study · 1273 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

HIV Transmission or Death at 24 months among those uninfected at birth · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission or Death at 24 months among those uninfected at birth compared with an extended NVP regimen administered to infants (moderate certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
HR 1 [0.75, 1.34]
1 study · 1122 participants
Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
RR 1.66 [1.16, 2.37]
1 study · 2013 participants
Low

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

It is very uncertain whether an extended NVP plus ZDV dual regimen administered to infants for 14… changes infants with Probably Related Severe Adverse Events compared with an extended NVP regimen administered to infants (very low certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
RR 1.02 [0.33, 3.15]
1 study · 2013 participants
Very low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Quality of life ‐ total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 204 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Individualised pressure ulcer education and monthly structured telephone follow‐up vs standard pressure ulcer education and monthly mail or telephone follow‐up

Time to occurrence of new ulcer · s

The review found no eligible studies for this question.

1 finding from 1 review

Patient and lay carer education for preventing pressure ulceration in at‐risk populations 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Individualised pressure ulcer education and monthly structured telephone follow‐up vs standard pressure ulcer education and monthly mail or telephone follow‐up

Proportion of participants developing a new ulcer · s

It is very uncertain whether individualised pressure ulcer education and monthly structured… changes proportion of participants developing a new ulcer (24 months) compared with standard pressure ulcer education and monthly mail or telephone… (very low certainty).

1 finding from 1 review

Patient and lay carer education for preventing pressure ulceration in at‐risk populations 2021 · Cochrane Headline outcomes only
RR 0.55 [0.23, 1.3]
1 study · 31 participants
Very low

Individualised pressure ulcer education and monthly structured telephone follow‐up vs standard pressure ulcer education and quarterly mail or telephone follow‐up,

Time to occurrence of new ulcer · s

The review found no eligible studies for this question.

1 finding from 1 review

Patient and lay carer education for preventing pressure ulceration in at‐risk populations 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Individualised pressure ulcer education and monthly structured telephone follow‐up vs standard pressure ulcer education and quarterly mail or telephone follow‐up,

Proportion of participants developing a new ulcer · s

1 finding from 1 review

Patient and lay carer education for preventing pressure ulceration in at‐risk populations 2021 · Cochrane Headline outcomes only
RR 0.33 [0.17, 0.67]
1 study · 31 participants
Very low